禮來公司的三重激動劑瑞他曲肽顯著改善了體重、糖化血紅蛋白A1C、膝骨關節炎疼痛和阻塞性睡眠呼吸中止，展現了其在治療肥胖及其併發症方面的卓越潛力。
印第安納波利斯，2026年6月6日/PRNewswire/ -- Zepbound（替澤帕肽）和Foundayo（奧福格列酮）的生產商禮來公司（NYSE：LLY）今日宣布，其新藥retatrutide的關鍵性3期臨床試驗取得了更多積極結果…
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Frequently Asked Questions
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
